Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07066657 · ClinicalTrials.gov registry record · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Cancer, sponsored by ArriVent BioPharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 405
- Enrollment target
- 15
- Study locations
NCT07066657: Recruiting Phase 1 study of Colorectal Cancer and Pancreatic Cancer, sponsored by ArriVent BioPharma.
NCT07066657 is a Phase 1 study of Colorectal Cancer and Pancreatic Cancer that is actively recruiting participants, run by ArriVent BioPharma. The registered enrollment target is 405 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (74% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07066657, a Phase 1 study of Colorectal Cancer and Pancreatic Cancer, is actively recruiting participants, sponsored by ArriVent BioPharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 405 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG MRG007
Study Locations (15)
California
- ULCA - Los Angeles
- UCSF - San Francisco
Colorado
- University of Colorado - Aurora
- Sarah Cannon Research Institute - Denver
Texas
- MD Anderson Cancer Center - Houston
- NEXT Dallas - Irving
Shanghai Municipality
- Renji Hospital Shanghai Jiaotong University School of Medicine - Shanghai
- Zhongshan Hospital Fudan University - Shanghai
Florida
- Sarah Cannon Research Institute - Sarasota
Tennessee
- Sarah Cannon Research Institute - Nashville
Virginia
- NEXT Virginia - Fairfax
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2025-07-25 |
| Est. Completion | 2030-12 |
| Phase | Phase 1 |
What NCT07066657 shows while recruiting
NCT07066657 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (74% lower).
The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRG007 is the first listed.
NCT07066657 lists 15 locations in 11 states (California, Colorado, Texas).
Frequently Asked Questions
What is clinical trial NCT07066657 about?
NCT07066657 is a clinical study titled "A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors". This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
What is the current status of trial NCT07066657?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 405 participants. The study started on 2025-07-25. Estimated completion is 2030-12.
What conditions does trial NCT07066657 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Locally Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT07066657?
The interventions under investigation include: MRG007 (DRUG).
Who is sponsoring clinical trial NCT07066657?
This trial is sponsored by ArriVent BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07066657 being conducted?
This trial has 15 study locations across California, Colorado, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07066657's enrollment target sits among peer trials
405 90th of 381 higher than 292 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
- NCT06585787 · 406 participants · Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI